Stockreport

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights [Yahoo! Finance]

Passage Bio, Inc.  (PASG) 
PDF Passage Bio Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study Treated first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of upliFT-D [Read more]